Display options
Cite
Gambardella A, Licata G, Calabrese G, et al. CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab. Psoriasis (Auckl). 2020;10:57-60doi: 10.2147/PTT.S284701.
Gambardella, A., Licata, G., Calabrese, G., De Rosa, A., Pagliuca, F., Alfano, R., & Argenziano, G. (2020). CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab. Psoriasis (Auckland, N.Z.), 1057-60. https://doi.org/10.2147/PTT.S284701
Gambardella, Alessio, et al. "CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab." Psoriasis (Auckland, N.Z.) vol. 10 (2020): 57-60. doi: https://doi.org/10.2147/PTT.S284701
Gambardella A, Licata G, Calabrese G, De Rosa A, Pagliuca F, Alfano R, Argenziano G. CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab. Psoriasis (Auckl). 2020 Nov 27;10:57-60. doi: 10.2147/PTT.S284701. eCollection 2020. PMID: 33282718; PMCID: PMC7711202.
Copy Download .nbib Format: NLM
Share it on

Psoriasis (Auckl). 2020 Nov 27;10:57-60. doi: 10.2147/PTT.S284701. eCollection 2020.

CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab.

Psoriasis (Auckland, N.Z.)

Alessio Gambardella, Gaetano Licata, Giulia Calabrese, Alina De Rosa, Francesca Pagliuca, Roberto Alfano, Giuseppe Argenziano

Affiliations

  1. Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  2. Division of Pathology, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  3. Department of Anesthesiology, Surgery and Emergency, University of Campania Luigi Vanvitelli, Naples, Italy.

PMID: 33282718 PMCID: PMC7711202 DOI: 10.2147/PTT.S284701

Abstract

The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases.

© 2020 Gambardella et al.

Keywords: anti-TNF-α therapy; biological therapy; case report; cytomegalovirus; immune-mediated inflammatory diseases; psoriasis

Conflict of interest statement

The authors declare no conflicts of interest in this work.

References

  1. J Infect. 2002 Feb;44(2):78-83 - PubMed
  2. Reumatismo. 2016 Dec 16;68(3):144-147 - PubMed
  3. Med Microbiol Immunol. 2019 Aug;208(3-4):415-429 - PubMed
  4. Acta Derm Venereol. 2008;88(5):523-4 - PubMed
  5. Dermatology. 2009;218(1):84-5 - PubMed
  6. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514 - PubMed
  7. Infect Disord Drug Targets. 2011 Oct;11(5):466-74 - PubMed
  8. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1365-9 - PubMed
  9. Arch Dermatol. 2009 Aug;145(8):961-2 - PubMed
  10. Int J Dermatol. 2016 Nov;55(11):e600-e602 - PubMed

Publication Types